<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="39626">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590536</url>
  </required_header>
  <id_info>
    <org_study_id>SFGR</org_study_id>
    <nct_id>NCT02590536</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction</brief_title>
  <official_title>A Randomized Controlled Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <brief_summary>
    <textblock>
      This is a Randomized Controlled Trial to evaluate the effect of sildenafil on Doppler
      velocity indices of the umbilical arteries in patients with placental insufficiency and
      fetal growth restriction, and if sildenafil can improve fetal and neonatal outcomes in those
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Doppler velocity indices, Resistance index (RI) and the pulsatility index (PI), of the umbilical arteries and fetal middle cerebral artery as a Ratio</measure>
    <time_frame>24 weeks to 34 weeks of gestation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neonatal birth weight in grams</measure>
    <time_frame>At time of Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery in weeks</measure>
    <time_frame>At time of Delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal complication rates including Intraventricular hemorrhage (IVH) , Neonatal Necrotizing Enterocolitis (NEC) , Syndrome Respiratory Distress (RDS) , Neonatal anemia, Neonatal blood transfusion).</measure>
    <time_frame>The first 28 day of delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal ICU admission rate</measure>
    <time_frame>The first 28 day of delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fetal Growth Retardation</condition>
  <arm_group>
    <arm_group_label>sildenafil citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil citrate</intervention_name>
    <description>In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.
This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet.</description>
    <arm_group_label>sildenafil citrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women, singleton pregnancy, gestational age 24-34 weeks, with

               -  Fetal growth restriction.

               -  Intact membranes.

               -  Abnormal umbilical artery Doppler waveforms.

          -  Fetal abdominal circumference at or below the tenth percentile.

          -  Normal venous fetal Doppler

        Exclusion Criteria:

          -  Undetermined gestational age.

          -  Intrauterine infection.

          -  High Risk for aneuploidy (e.g. maternal age â‰¥40 years, detected congenital fetal
             anomalies in the current or previous pregnancies).

          -  Maternal cardiovascular morbidity.

          -  Users of any vasodilator agents.

          -  Known allergy to sildenafil citrate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed A. Shafy El-Shahawy, MD</last_name>
    <phone>+202 01223266380</phone>
    <email>ahmedshafy@hotmail.com</email>
  </overall_contact>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 28, 2015</lastchanged_date>
  <firstreceived_date>October 21, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ahmed Abdel Shafy El Shahawy</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>Sildenafil</keyword>
  <keyword>Fetal growth Restriction</keyword>
  <keyword>Umbilical Artery Doppler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fetal Growth Retardation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
